These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11438556)

  • 1. STI571 revolution: can the newer targeted drugs measure up?
    Garber K
    J Natl Cancer Inst; 2001 Jul; 93(13):970-3. PubMed ID: 11438556
    [No Abstract]   [Full Text] [Related]  

  • 2. After 30 years of laboratory work, a quick approval for STI571.
    Arnold K
    J Natl Cancer Inst; 2001 Jul; 93(13):972. PubMed ID: 11438558
    [No Abstract]   [Full Text] [Related]  

  • 3. [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
    Ray-Coquard I; Blay JY
    Bull Cancer; 2002 Jun; 89(6):567-9. PubMed ID: 12135855
    [No Abstract]   [Full Text] [Related]  

  • 4. STI571: a magic bullet?
    Verweij J; Judson I; van Oosterom A
    Eur J Cancer; 2001 Oct; 37(15):1816-9. PubMed ID: 11576833
    [No Abstract]   [Full Text] [Related]  

  • 5. STI571: a paradigm of new agents for cancer therapeutics.
    Mauro MJ; O'Dwyer M; Heinrich MC; Druker BJ
    J Clin Oncol; 2002 Jan; 20(1):325-34. PubMed ID: 11773186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of chronic myelogenous leukemia by using imatinib].
    Jinnai I
    Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1819-24. PubMed ID: 16223141
    [No Abstract]   [Full Text] [Related]  

  • 7. Imatinib (Gleevec) as a paradigm of targeted cancer therapies.
    Druker B
    Keio J Med; 2010; 59(1):1-3. PubMed ID: 20375651
    [No Abstract]   [Full Text] [Related]  

  • 8. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?
    Yeung DT; White DL
    Leuk Lymphoma; 2011 Feb; 52(2):165-7. PubMed ID: 21171867
    [No Abstract]   [Full Text] [Related]  

  • 10. STI-571 in chronic myelogenous leukaemia.
    Tsao AS; Kantarijian H; Talpaz M
    Br J Haematol; 2002 Oct; 119(1):15-24. PubMed ID: 12358949
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer in the crosshairs.
    Martindale D
    Sci Am; 2001 Sep; 285(3):19-20. PubMed ID: 11524965
    [No Abstract]   [Full Text] [Related]  

  • 12. 21st-century oncology: a tangled web.
    Keating P; Cambrosio A
    Lancet; 2013 Dec; 382(9909):e45-6. PubMed ID: 24350356
    [No Abstract]   [Full Text] [Related]  

  • 13. David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies.
    Druker BJ
    J Clin Oncol; 2003 Dec; 21(23 Suppl):239s-245s. PubMed ID: 14645403
    [No Abstract]   [Full Text] [Related]  

  • 14. Small molecule: large hopes.
    Szer J; Lieschke GJ
    Intern Med J; 2001; 31(7):382-3. PubMed ID: 11584898
    [No Abstract]   [Full Text] [Related]  

  • 15. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Barbour V
    Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557
    [No Abstract]   [Full Text] [Related]  

  • 16. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
    Nakajima M; Toga W
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate induced immune thrombocytopenia.
    Rajappa S; Varadpande L; Paul TR; Digumarti R
    Leuk Lymphoma; 2007 Nov; 48(11):2261-3. PubMed ID: 17926182
    [No Abstract]   [Full Text] [Related]  

  • 18. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NICE widens patient group for leukaemia drug.
    Kmietowicz Z;
    BMJ; 2002 Oct; 325(7369):852. PubMed ID: 12386018
    [No Abstract]   [Full Text] [Related]  

  • 20. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
    Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.